Skip to main content
. 2017 Jul 12;10(5):719–725. doi: 10.1016/j.tranon.2017.06.004

Figure 1.

Figure 1

Kaplan-Meier survival curves for RFS according to inflammation-based scores in 226 patients with acral melanoma. (A) Ninety-three patients with NLR ≥2.35 had shorter median RFS than 133 patients with NLR <2.35 (15 vs 30.2 months, P=.005). (B) One hundred seven patients with PLR ≥129 had shorter median RFS than 119 patients with PLR <129 (12 vs 27.4 months, P=.002). (C) One hundred eleven patients with SII ≥615×109/l had shorter median RFS than 115 patients with SII <615×109/l (14.8 vs 30.2 months, P=.029). (D) ROC curves of NLR, PLR, SII, and AJCC M stage for RFS, with a median survival time of 22.3 months.